Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial

TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(16)30457-0 ◽

2016 ◽

Vol 67 (13) ◽

pp. 456

Author(s):

Francesco Costa ◽

Marco Valgimigli ◽

Yuliya Lokhnygina ◽

Robert Clare ◽

Lars Wallentin ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Randomized Trial ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

10.1016/j.ahj.2017.10.007 ◽

2018 ◽

Vol 196 ◽

pp. 28-35 ◽

Cited By ~ 5

Author(s):

Patrícia O. Guimarães ◽

Sergio Leonardi ◽

Zhen Huang ◽

Lars Wallentin ◽

Frans Van de Werf ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Features ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Faculty Opinions recommendation of Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717992295.793487025 ◽

2013 ◽

Author(s):

Venu Menon ◽

Bhuvnesh Aggarwal

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

European Heart Journal ◽

10.1093/eurheartj/ehw525 ◽

2016 ◽

pp. ehw525 ◽

Cited By ~ 16

Author(s):

Marco Valgimigli ◽

Francesco Costa ◽

Yuliya Lokhnygina ◽

Robert M. Clare ◽

Lars Wallentin ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Coronary Syndrome ◽

Randomized Trial ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Trade Off ◽

Coronary Syndrome ◽

Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

10.1016/j.ahj.2016.05.012 ◽

2016 ◽

Vol 178 ◽

pp. 176-184 ◽

Cited By ~ 4

Author(s):

Luciana V. Armaganijan ◽

Karen P. Alexander ◽

Zhen Huang ◽

Pierluigi Tricoci ◽

Claes Held ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Clinical Event ◽

Thrombin Receptor ◽

Efficacy And Safety ◽

St Segment Elevation ◽

Coronary Syndrome ◽

St Segment ◽

Thrombin Receptor Antagonist ◽

Effect Of Age

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale

10.1016/j.ahj.2009.07.001 ◽

2009 ◽

Vol 158 (3) ◽

pp. 327-334.e4 ◽

Cited By ~ 93

Author(s):

The TRA•CER Executive and Steering Committees

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Study Design ◽

Clinical Event ◽

Thrombin Receptor ◽

Coronary Syndrome ◽

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)

10.1016/j.ahj.2014.06.017 ◽

2014 ◽

Vol 168 (4) ◽

pp. 588-596 ◽

Cited By ~ 28

Author(s):

William Schuyler Jones ◽

Pierluigi Tricoci ◽

Zhen Huang ◽

David J. Moliterno ◽

Robert A. Harrington ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Peripheral Artery Disease ◽

Clinical Event ◽

Thrombin Receptor ◽

Peripheral Artery ◽

Coronary Syndrome ◽

Artery Disease ◽

Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial

10.1016/j.ahj.2014.09.002 ◽

2014 ◽

Vol 168 (6) ◽

pp. 869-877.e1 ◽

Cited By ~ 15

Author(s):

Pierluigi Tricoci ◽

Yuliya Lokhnygina ◽

Zhen Huang ◽

Frans Van de Werf ◽

Jan H. Cornel ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Acute Coronary Syndromes ◽

Clinical Event ◽

Thrombin Receptor ◽

St Segment Elevation ◽

Coronary Syndrome ◽

St Segment ◽

Coronary Syndromes ◽

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial

European Heart Journal Acute Cardiovascular Care ◽

10.1177/2048872614527838 ◽

2014 ◽

Vol 3 (3) ◽

pp. 246-256 ◽

Cited By ~ 8

Author(s):

Claes Held ◽

Pierluigi Tricoci ◽

Zhen Huang ◽

Frans Van de Werf ◽

Harvey D White ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Receptor Antagonist ◽

Thrombin Receptor ◽

St Segment Elevation ◽

Coronary Syndrome ◽

St Segment ◽

Elevation Acute Coronary Syndrome ◽

Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA-2P–TIMI50) Trial

Circulation ◽

10.1161/circulationaha.115.015471 ◽

2015 ◽

Vol 131 (12) ◽

pp. 1041-1043 ◽

Cited By ~ 7

Author(s):

Shinichi Goto ◽

Shinya Goto

Keyword(s):

Myocardial Infarction ◽

Clinical Trial ◽

Secondary Prevention ◽

Receptor Antagonist ◽

Patient Population ◽

Thrombin Receptor ◽

Large Clinical Trial ◽

Ischemic Events ◽

Thrombin Receptor Antagonist ◽

Selection Of